Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep;81(2):203–211. doi: 10.1038/sj.bjc.6690678

Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies

C Holst-Hansen 1, M J A G Hamers 1, B E Johannessen 1, N Brünner 1, R W Stephens 1
PMCID: PMC2362879  PMID: 10496343

Abstract

The urokinase plasminogen activator receptor (uPAR) plays a critical role in urokinase-mediated plasminogen activation and thereby in the process leading to invasion and metastasis. Soluble urokinase receptor (suPAR) is released from tumours, and in cancer patients the blood level of soluble receptor is increased. Using an enzyme-linked, immunosorbent assay (ELISA)-specific for the human urokinase receptor, release of soluble receptor was measured in cultures of human breast carcinoma cells, in tumour extracts and in plasma from mice with xenografted human tumours. Soluble human urokinase receptor (shuPAR) was released into culture supernatant during the growth of the human breast cancer cell line MDA-MB-231 BAG, and the level of shuPAR in conditioned medium determined by ELISA was a linear function of both viable cell number and time of incubation. Western blotting showed that the form of shuPAR measured by ELISA in conditioned medium consisted virtually exclusively of the three-domain full-length protein, while uPAR in cell lysates consisted of full-length uPAR as well as the domains (2+3) cleavage product. shuPAR was also released into the plasma of nude mice during growth of MDA-MB-231 BAG, MDA-MB-435 BAG and HCT 116 cells as subcutaneously xenografted tumours. Western blotting demonstrated that the shuPAR released from the xenografted human tumours into plasma consisted of the three-domain full-length protein, despite the finding of some cleaved uPAR in detergent extracts of tumour tissue. The levels of shuPAR determined by ELISA in the plasma of host mice during the growth of xenografted cell lines were highly correlated with tumour volume. © 1999 Cancer Research Campaign

Keywords: uPAR, soluble receptor, human cancer xenografts

Full Text

The Full Text of this article is available as a PDF (141.9 KB).

Footnotes

The Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, Bld 86.2, DK-2100 Copenhagen Ø, Denmark

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen P. A., Kjøller L., Christensen L., Duffy M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997 Jul 3;72(1):1–22. doi: 10.1002/(sici)1097-0215(19970703)72:1<1::aid-ijc1>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  2. Baramova E. N., Bajou K., Remacle A., L'Hoir C., Krell H. W., Weidle U. H., Noel A., Foidart J. M. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett. 1997 Mar 24;405(2):157–162. doi: 10.1016/s0014-5793(97)00175-0. [DOI] [PubMed] [Google Scholar]
  3. Behrendt N., Rønne E., Ploug M., Petri T., Løber D., Nielsen L. S., Schleuning W. D., Blasi F., Appella E., Danø K. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem. 1990 Apr 15;265(11):6453–6460. [PubMed] [Google Scholar]
  4. Brünner N., Thompson E. W., Spang-Thomsen M., Rygaard J., Danø K., Zwiebel J. A. lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. Eur J Cancer. 1992;28A(12):1989–1995. doi: 10.1016/0959-8049(92)90245-w. [DOI] [PubMed] [Google Scholar]
  5. Chavakis T., Kanse S. M., Yutzy B., Lijnen H. R., Preissner K. T. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood. 1998 Apr 1;91(7):2305–2312. [PubMed] [Google Scholar]
  6. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  7. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  8. Deng G., Curriden S. A., Wang S., Rosenberg S., Loskutoff D. J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol. 1996 Sep;134(6):1563–1571. doi: 10.1083/jcb.134.6.1563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ellis V., Behrendt N., Danø K. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem. 1991 Jul 5;266(19):12752–12758. [PubMed] [Google Scholar]
  10. Feinberg A. P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983 Jul 1;132(1):6–13. doi: 10.1016/0003-2697(83)90418-9. [DOI] [PubMed] [Google Scholar]
  11. Ganesh S., Sier C. F., Heerding M. M., Griffioen G., Lamers C. B., Verspaget H. W. Urokinase receptor and colorectal cancer survival. Lancet. 1994 Aug 6;344(8919):401–402. doi: 10.1016/s0140-6736(94)91427-3. [DOI] [PubMed] [Google Scholar]
  12. Ginestra A., Monea S., Seghezzi G., Dolo V., Nagase H., Mignatti P., Vittorelli M. L. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem. 1997 Jul 4;272(27):17216–17222. doi: 10.1074/jbc.272.27.17216. [DOI] [PubMed] [Google Scholar]
  13. Grøndahl-Hansen J., Peters H. A., van Putten W. L., Look M. P., Pappot H., Rønne E., Dano K., Klijn J. G., Brünner N., Foekens J. A. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res. 1995 Oct;1(10):1079–1087. [PubMed] [Google Scholar]
  14. HE C. S., Wilhelm S. M., Pentland A. P., Marmer B. L., Grant G. A., Eisen A. Z., Goldberg G. I. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A. 1989 Apr;86(8):2632–2636. doi: 10.1073/pnas.86.8.2632. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Holst-Hansen C., Johannessen B., Høyer-Hansen G., Rømer J., Ellis V., Brünner N. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis. 1996 May;14(3):297–307. doi: 10.1007/BF00053903. [DOI] [PubMed] [Google Scholar]
  16. Høyer-Hansen G., Behrendt N., Ploug M., Danø K., Preissner K. T. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 1997 Dec 22;420(1):79–85. doi: 10.1016/s0014-5793(97)01491-9. [DOI] [PubMed] [Google Scholar]
  17. Lau H. K., Kim M. Soluble urokinase receptor from fibrosarcoma HT-1080 cells. Blood Coagul Fibrinolysis. 1994 Aug;5(4):473–478. [PubMed] [Google Scholar]
  18. Lyons R. M., Gentry L. E., Purchio A. F., Moses H. L. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol. 1990 Apr;110(4):1361–1367. doi: 10.1083/jcb.110.4.1361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Masucci M. T., Pedersen N., Blasi F. A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor. J Biol Chem. 1991 May 15;266(14):8655–8658. [PubMed] [Google Scholar]
  20. Pappot H., Høyer-Hansen G., Rønne E., Hansen H. H., Brünner N., Danø K., Grøndahl-Hansen J. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer. 1997 May;33(6):867–872. doi: 10.1016/s0959-8049(96)00523-0. [DOI] [PubMed] [Google Scholar]
  21. Pedersen H., Brünner N., Francis D., Osterlind K., Rønne E., Hansen H. H., Danø K., Grøndahl-Hansen J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 1994 Sep 1;54(17):4671–4675. [PubMed] [Google Scholar]
  22. Pedersen N., Schmitt M., Rønne E., Nicoletti M. I., Høyer-Hansen G., Conese M., Giavazzi R., Dano K., Kuhn W., Jänicke F. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest. 1993 Nov;92(5):2160–2167. doi: 10.1172/JCI116817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Plesner T., Behrendt N., Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells. 1997;15(6):398–408. doi: 10.1002/stem.150398. [DOI] [PubMed] [Google Scholar]
  24. Ploug M., Ellis V., Danø K. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry. 1994 Aug 2;33(30):8991–8997. doi: 10.1021/bi00196a017. [DOI] [PubMed] [Google Scholar]
  25. Ploug M., Ostergaard S., Hansen L. B., Holm A., Danø K. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry. 1998 Mar 17;37(11):3612–3622. doi: 10.1021/bi972787k. [DOI] [PubMed] [Google Scholar]
  26. Ploug M., Rønne E., Behrendt N., Jensen A. L., Blasi F., Danø K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem. 1991 Jan 25;266(3):1926–1933. [PubMed] [Google Scholar]
  27. Ponte P., Ng S. Y., Engel J., Gunning P., Kedes L. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res. 1984 Feb 10;12(3):1687–1696. doi: 10.1093/nar/12.3.1687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Pyke C., Graem N., Ralfkiaer E., Rønne E., Høyer-Hansen G., Brünner N., Danø K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res. 1993 Apr 15;53(8):1911–1915. [PubMed] [Google Scholar]
  29. Pyke C., Kristensen P., Ralfkiaer E., Grøndahl-Hansen J., Eriksen J., Blasi F., Danø K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol. 1991 May;138(5):1059–1067. [PMC free article] [PubMed] [Google Scholar]
  30. Resnati M., Guttinger M., Valcamonica S., Sidenius N., Blasi F., Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 1996 Apr 1;15(7):1572–1582. [PMC free article] [PubMed] [Google Scholar]
  31. Roldan A. L., Cubellis M. V., Masucci M. T., Behrendt N., Lund L. R., Danø K., Appella E., Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. 1990 Feb;9(2):467–474. doi: 10.1002/j.1460-2075.1990.tb08132.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Rømer J., Pyke C., Lund L. R., Eriksen J., Kristensen P., Rønne E., Høyer-Hansen G., Danø K., Brünner N. Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int J Cancer. 1994 May 15;57(4):553–560. doi: 10.1002/ijc.2910570419. [DOI] [PubMed] [Google Scholar]
  33. Rønne E., Behrendt N., Ploug M., Nielsen H. J., Wöllisch E., Weidle U., Danø K., Høyer-Hansen G. Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. J Immunol Methods. 1994 Jan 3;167(1-2):91–101. doi: 10.1016/0022-1759(94)90078-7. [DOI] [PubMed] [Google Scholar]
  34. Rønne E., Høyer-Hansen G., Brünner N., Pedersen H., Rank F., Osborne C. K., Clark G. M., Danø K., Grøndahl-Hansen J. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat. 1995 Mar;33(3):199–207. doi: 10.1007/BF00665944. [DOI] [PubMed] [Google Scholar]
  35. Rønne E., Pappot H., Grøndahl-Hansen J., Høyer-Hansen G., Plesner T., Hansen N. E., Danø K. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1995 Mar;89(3):576–581. doi: 10.1111/j.1365-2141.1995.tb08366.x. [DOI] [PubMed] [Google Scholar]
  36. Shapiro R. L., Duquette J. G., Roses D. F., Nunes I., Harris M. N., Kamino H., Wilson E. L., Rifkin D. B. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res. 1996 Aug 1;56(15):3597–3604. [PubMed] [Google Scholar]
  37. Sier C. F., Stephens R., Bizik J., Mariani A., Bassan M., Pedersen N., Frigerio L., Ferrari A., Danø K., Brünner N. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res. 1998 May 1;58(9):1843–1849. [PubMed] [Google Scholar]
  38. Solberg H., Rømer J., Brünner N., Holm A., Sidenius N., Danø K., Høyer-Hansen G. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer. 1994 Sep 15;58(6):877–881. doi: 10.1002/ijc.2910580622. [DOI] [PubMed] [Google Scholar]
  39. Stephens R. W., Nielsen H. J., Christensen I. J., Thorlacius-Ussing O., Sørensen S., Danø K., Brünner N. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst. 1999 May 19;91(10):869–874. doi: 10.1093/jnci/91.10.869. [DOI] [PubMed] [Google Scholar]
  40. Stephens R. W., Pedersen A. N., Nielsen H. J., Hamers M. J., Høyer-Hansen G., Rønne E., Dybkjaer E., Danø K., Brünner N. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem. 1997 Oct;43(10):1868–1876. [PubMed] [Google Scholar]
  41. Wilhelm O., Weidle U., Höhl S., Rettenberger P., Schmitt M., Graeff H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett. 1994 Jan 10;337(2):131–134. doi: 10.1016/0014-5793(94)80259-9. [DOI] [PubMed] [Google Scholar]
  42. Wohn K. D., Kanse S. M., Deutsch V., Schmidt T., Eldor A., Preissner K. T. The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage. Thromb Haemost. 1997 Mar;77(3):540–547. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES